Retatrutide Study Results Timeline

Retatrutide has produced some of the most significant weight reduction outcomes observed in incretin-based clinical research to date. Published Phase 2 trial data evaluated multiple weekly dosing groups over 24 and 48 week periods using gradual dose-escalation protocols.

For current availability, see our:

Week 1–4: Initial Dose Escalation

The clinical studies began with lower introductory weekly dosing before gradually escalating participants toward higher maintenance dose ranges.

During the first month, researchers commonly observed:

  • appetite reduction,
  • earlier satiety,
  • and decreased caloric intake patterns.

The early phase focused heavily on tolerability while preparing participants for continued escalation throughout the study duration.

 

Further Reading

Where To Buy  Retatrutide In Australia 

Week 24 Clinical Study Results

Retatrutide Study Results Timeline

At 24 weeks, researchers reported the following average body weight reductions:

  • 1 mg: 7.2%
  • 4 mg: 12.9%
  • 8 mg: 17.3%
  • 12 mg: 17.5%
  • Placebo: 1.6%

The higher-dose groups demonstrated substantially greater reductions compared with placebo groups during the first 24 weeks of treatment.

Researchers also noted that many participants were still progressing without evidence of a full plateau.

Researchers evaluating longer-duration exposure protocols often focused on higher maintenance ranges similar to those discussed in our Where to Buy Retatrutide Australia research overview.

Week 48 Clinical Study Results

Retatrutide Study Results Timeline

At 48 weeks, the study demonstrated continued progression across higher-dose groups:

  • 1 mg: 8.7%
  • 4 mg: 17.1%
  • 8 mg: 22.8%
  • 12 mg: 24.2%
  • Placebo: 2.1%

The 12 mg group produced the largest average reductions observed during the published study period.

Importantly, researchers stated that many participants continued progressing throughout the extended treatment duration without a definitive plateau being reached.

Why Retatrutide Research Has Drawn Attention

Unlike earlier single-pathway compounds, Retatrutide targets multiple metabolic pathways simultaneously.

Researchers believe this multi-receptor mechanism may explain:

  • Stronger appetite regulation
  • Larger long-term weight reduction outcomes
  • Broader metabolic effects observed during trials

As larger Phase 3 programs continue globally, research interest surrounding Retatrutide remains extremely high.

Research Disclaimer

This page is provided strictly for informational and research discussion purposes only.

Retatrutide is an investigational compound currently undergoing clinical evaluation. It is not approved for general consumer use in Australia outside authorised medical and research pathways.

All references above relate to published research findings and clinical trial observations, not guaranteed outcomes.